Acetyldinaline
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Acetyldinaline
- DrugBank Accession Number
- DB16142
- Background
Acetyldinaline is under investigation in clinical trial NCT00005624 (CI-994 in Treating Patients With Advanced Myeloma).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 227.267
Monoisotopic: 227.105862051 - Chemical Formula
- C13H13N3O
- Synonyms
- Dinalin
- Dinaline
- External IDs
- NSC-328786
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- RG9G4Z82PY
- CAS number
- 58338-59-3
- InChI Key
- QGMGHALXLXKCBD-UHFFFAOYSA-N
- InChI
- InChI=1S/C13H13N3O/c14-10-7-5-9(6-8-10)13(17)16-12-4-2-1-3-11(12)15/h1-8H,14-15H2,(H,16,17)
- IUPAC Name
- 4-amino-N-(2-aminophenyl)benzamide
- SMILES
- NC1=CC=C(C=C1)C(=O)NC1=CC=CC=C1N
References
- General References
- Not Available
- External Links
- ChemSpider
- 38972
- BindingDB
- 115054
- ChEMBL
- CHEMBL1351761
- ZINC
- ZINC000000001310
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 2 Completed Treatment Multiple Myeloma (MM) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.167 mg/mL ALOGPS logP 0.85 ALOGPS logP 1.41 Chemaxon logS -3.1 ALOGPS pKa (Strongest Acidic) 16.14 Chemaxon pKa (Strongest Basic) 3.46 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 81.14 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 70.99 m3·mol-1 Chemaxon Polarizability 24.52 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-00di-0900000000-92480266f49f8eaa348d Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-2090000000-6221494b3a0d10820a2a Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-00di-0930000000-bc4993186e50719b6d1a Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-005i-1940000000-a1d3f7383a78d57b97bb Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-00kf-9100000000-51b80cee2d42f8b18562 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-9300000000-8021256733e94a559e38 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 163.7588601 predictedDarkChem Lite v0.1.0 [M-H]- 151.25404 predictedDeepCCS 1.0 (2019) [M+H]+ 164.2593601 predictedDarkChem Lite v0.1.0 [M+H]+ 153.61205 predictedDeepCCS 1.0 (2019) [M+Na]+ 163.4027601 predictedDarkChem Lite v0.1.0 [M+Na]+ 159.70518 predictedDeepCCS 1.0 (2019)
Drug created at December 15, 2020 18:13 / Updated at December 20, 2020 03:37